Malin Corporation PLC (MLLNF) has released an update.
Malin Corporation PLC has announced that its investee, Poseida Therapeutics, entered a significant research collaboration and licensing deal with Xyphos Biosciences, aiming to develop innovative CAR-T therapies for solid tumors. Poseida is set to receive an upfront payment of $50 million, with the potential for up to $550 million in additional milestones and royalties. The partnership marries Poseida’s allogeneic CAR-T platform with…
Read More…
Malin Investee Poseida Forges Major Biotech Alliance
